세계의 길랑-바레 증후군(GBS) 진단 시장(2025-2032년) : 업계 분석, 규모, 점유율, 성장, 동향, 예측

Persistence Market Research has recently released a comprehensive report on the global Guillain-Barre Syndrome (GBS) Diagnostics Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Guillain-Barre Syndrome Diagnostics Market Size (2025E): US$ 143.1 Mn
• Projected Market Value (2032F): US$ 180.8 Mn
• Global Market Growth Rate (CAGR 2025 to 2032): 3.4%

Guillain-Barre Syndrome Diagnostics Market - Report Scope:

The Guillain-Barre Syndrome diagnostics market comprises a range of diagnostic tests and technologies used to detect and monitor this rare but serious neurological disorder. These diagnostics include lumbar punctures, nerve conduction studies, EMG, blood tests, and other advanced techniques to assess nerve function and immune response. The market is expanding due to growing awareness about autoimmune neurological disorders, increasing incidence of GBS linked to infections and vaccinations, and advancements in diagnostic accuracy and speed.

Market Growth Drivers:

The global Guillain-Barre Syndrome diagnostics market is witnessing significant growth, fueled by several critical drivers. Rising prevalence of neurological and autoimmune disorders, coupled with improved access to healthcare infrastructure, has led to greater demand for early and accurate diagnostics. Awareness campaigns by healthcare organizations and government initiatives promoting early diagnosis are also contributing to market growth. Furthermore, increasing research and clinical focus on post-viral neurological complications-including those associated with Zika virus and COVID-19-have heightened the need for robust diagnostic capabilities. Technological advancements such as more sensitive EMG systems and rapid blood assays further bolster the adoption of these diagnostics.

Market Restraints:

Despite positive market trends, certain factors may hinder the growth trajectory of the Guillain-Barre Syndrome diagnostics market. Limited awareness in low- and middle-income countries and a general lack of neurological diagnostic expertise pose challenges to early detection. High costs associated with advanced diagnostic modalities and testing infrastructure can also be prohibitive, especially in underfunded healthcare systems. Moreover, GBS being a rare condition may deter extensive investment in diagnostic development, limiting availability and affordability in some regions.

Market Opportunities:

The GBS diagnostics market holds promising opportunities owing to rising healthcare investments and the expansion of neurology-focused diagnostic centers worldwide. Emerging markets in Asia-Pacific and Latin America present lucrative growth potential due to increasing healthcare access and infrastructure development. Integration of AI and digital platforms in neurodiagnostics offers potential for faster and more accurate interpretations. Moreover, partnerships between diagnostic companies and research institutions can drive innovation in biomarker-based testing and point-of-care diagnostics, significantly improving patient outcomes and expanding the market reach.

Key Questions Answered in the Report:

• What are the primary factors driving the global Guillain-Barre Syndrome diagnostics market's growth?
• Which regions and diagnostic segments are experiencing the highest adoption rates?
• How are innovations in neurodiagnostic tools influencing market dynamics?
• Who are the key players in the Guillain-Barre Syndrome diagnostics market, and what strategies are they adopting?
• What are the emerging trends and future projections for the global GBS diagnostics market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Guillain-Barre Syndrome diagnostics market, such as Medtronic, Nihon Kohden, Natus Medical Incorporated, and Cadwell Industries, are focusing on product development, precision diagnostics, and global expansion strategies to strengthen their market position. These companies are investing in advanced EMG and nerve conduction systems, AI-assisted diagnostic tools, and strategic partnerships with hospitals and neurology centers. Emphasis on portable and user-friendly diagnostics and expansion into untapped regions further enhances their competitiveness and long-term growth prospects.

Companies Covered in This Report:

• Cadwell Industries, Inc.
• Alpine Biomed
• Bionen Medical Devices
• Cardinal Health
• Clarity Medical
• Deymed Diagnostic
• EMS Biomedical
• Medtronic
• Natus Medical Incorporated
• Nihon Kohden
• Rochester Electro-Medical (LifeSync)

Market Segmentation

By Diagnostic Test

• Lumbar Puncture
• Nerve Conduction
• Electromyography (EMG)
• Blood Test
• Other

By Syndrome Type

• Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
• Miller Fisher Syndrome (MFS)
• Acute Motor Axonal Neuropathy (AMAN)
• Others

By End-use

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Specialty Neurology Centers

By Region

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Guillain-Barre Syndrome Diagnostics Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. COVID-19 Impact Analysis
• 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Value Chain Analysis
• 3.2. Diagnostic Type Adoption / Usage Analysis
• 3.3. Prevalence & Incidence of GBS
• 3.4. Key Market Players
• 3.5. Regulatory Landscape
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis

4. Global Guillain-Barre Syndrome Diagnostics Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Mn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
• 4.3. Global Guillain-Barre Syndrome Diagnostics Market Outlook Diagnostic Type
  • 4.3.1. Historical Market Size (US$ Mn) Analysis, By Diagnostic Type, 2019-2024
  • 4.3.2. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
    • 4.3.2.1. Lumbar Puncture
    • 4.3.2.2. Nerve Conduction
    • 4.3.2.3. Electromyography (EMG)
    • 4.3.2.4. Blood Test
    • 4.3.2.5. Other
  • 4.3.3. Market Attractiveness Analysis: Diagnostic Type
• 4.4. Global Guillain-Barre Syndrome Diagnostics Market Outlook Syndrome Type
  • 4.4.1. Historical Market Size (US$ Mn) Analysis, By Syndrome Type, 2019-2024
  • 4.4.2. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
    • 4.4.2.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
    • 4.4.2.2. Miller Fisher Syndrome (MFS)
    • 4.4.2.3. Acute Motor Axonal Neuropathy (AMAN)
    • 4.4.2.4. Others
  • 4.4.3. Market Attractiveness Analysis: Syndrome Type
• 4.5. Global Guillain-Barre Syndrome Diagnostics Market Outlook End-use
  • 4.5.1. Historical Market Size (US$ Mn) Analysis, By End-use, 2019-2024
  • 4.5.2. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
    • 4.5.2.1. Hospitals and Clinics
    • 4.5.2.2. Diagnostic Laboratories
    • 4.5.2.3. Research & Academic Institutes
    • 4.5.2.4. Specialty Neurology Centers
  • 4.5.3. Market Attractiveness Analysis: End-use

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook Region

• 5.1. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
• 5.2. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
  • 5.2.1. North America
  • 5.2.2. Latin America
  • 5.2.3. Europe
  • 5.2.4. East Asia
  • 5.2.5. South Asia and Oceania
  • 5.2.6. Middle East & Africa
• 5.3. Market Attractiveness Analysis: Region

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

• 6.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 6.1.1. By Country
  • 6.1.2. By Diagnostic Type
  • 6.1.3. By Syndrome Type
  • 6.1.4. By End-use
• 6.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 6.2.1. U.S.
  • 6.2.2. Canada
• 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 6.3.1. Lumbar Puncture
  • 6.3.2. Nerve Conduction
  • 6.3.3. Electromyography (EMG)
  • 6.3.4. Blood Test
  • 6.3.5. Other
• 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 6.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 6.4.2. Miller Fisher Syndrome (MFS)
  • 6.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 6.4.4. Others
• 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 6.5.1. Hospitals and Clinics
  • 6.5.2. Diagnostic Laboratories
  • 6.5.3. Research & Academic Institutes
  • 6.5.4. Specialty Neurology Centers
• 6.6. Market Attractiveness Analysis

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

• 7.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 7.1.1. By Country
  • 7.1.2. By Diagnostic Type
  • 7.1.3. By Syndrome Type
  • 7.1.4. By Syndrome Type
  • 7.1.5. By End-use
• 7.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. U.K.
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Russia
  • 7.2.7. Rest of Europe
• 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 7.3.1. Lumbar Puncture
  • 7.3.2. Nerve Conduction
  • 7.3.3. Electromyography (EMG)
  • 7.3.4. Blood Test
  • 7.3.5. Other
• 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 7.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 7.4.2. Miller Fisher Syndrome (MFS)
  • 7.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 7.4.4. Others
• 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 7.5.1. Hospitals and Clinics
  • 7.5.2. Diagnostic Laboratories
  • 7.5.3. Research & Academic Institutes
  • 7.5.4. Specialty Neurology Centers
• 7.6. Market Attractiveness Analysis

8. East Asia Guillain-Barre Syndrome Diagnostics Market Outlook

• 8.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 8.1.1. By Country
  • 8.1.2. By Diagnostic Type
  • 8.1.3. By Syndrome Type
  • 8.1.4. By End-use
• 8.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 8.2.1. China
  • 8.2.2. Japan
  • 8.2.3. South Korea
• 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 8.3.1. Lumbar Puncture
  • 8.3.2. Nerve Conduction
  • 8.3.3. Electromyography (EMG)
  • 8.3.4. Blood Test
  • 8.3.5. Other
• 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 8.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 8.4.2. Miller Fisher Syndrome (MFS)
  • 8.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 8.4.4. Others
• 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 8.5.1. Hospitals and Clinics
  • 8.5.2. Diagnostic Laboratories
  • 8.5.3. Research & Academic Institutes
  • 8.5.4. Specialty Neurology Centers
• 8.6. Market Attractiveness Analysis

9. South Asia & Oceania Guillain-Barre Syndrome Diagnostics Market Outlook

• 9.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 9.1.1. By Country
  • 9.1.2. By Diagnostic Type
  • 9.1.3. By Syndrome Type
  • 9.1.4. By End-use
• 9.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 9.2.1. India
  • 9.2.2. Indonesia
  • 9.2.3. Thailand
  • 9.2.4. Singapore
  • 9.2.5. ANZ
  • 9.2.6. Rest of South Asia & Oceania
• 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 9.3.1. Lumbar Puncture
  • 9.3.2. Nerve Conduction
  • 9.3.3. Electromyography (EMG)
  • 9.3.4. Blood Test
  • 9.3.5. Other
• 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 9.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 9.4.2. Miller Fisher Syndrome (MFS)
  • 9.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 9.4.4. Others
• 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 9.5.1. Hospitals and Clinics
  • 9.5.2. Diagnostic Laboratories
  • 9.5.3. Research & Academic Institutes
  • 9.5.4. Specialty Neurology Centers
• 9.6. Market Attractiveness Analysis

10. Latin America Guillain-Barre Syndrome Diagnostics Market Outlook

• 10.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 10.1.1. By Country
  • 10.1.2. By Diagnostic Type
  • 10.1.3. By Syndrome Type
  • 10.1.4. By End-use
• 10.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 10.2.1. Brazil
  • 10.2.2. Mexico
  • 10.2.3. Rest of Latin America
• 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 10.3.1. Lumbar Puncture
  • 10.3.2. Nerve Conduction
  • 10.3.3. Electromyography (EMG)
  • 10.3.4. Blood Test
  • 10.3.5. Other
• 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 10.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 10.4.2. Miller Fisher Syndrome (MFS)
  • 10.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 10.4.4. Others
• 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 10.5.1. Hospitals and Clinics
  • 10.5.2. Diagnostic Laboratories
  • 10.5.3. Research & Academic Institutes
  • 10.5.4. Specialty Neurology Centers
• 10.6. Market Attractiveness Analysis

11. Middle East & Africa Guillain-Barre Syndrome Diagnostics Market Outlook

• 11.1. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
  • 11.1.1. By Country
  • 11.1.2. By Diagnostic Type
  • 11.1.3. By Syndrome Type
  • 11.1.4. By End-use
• 11.2. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
  • 11.2.1. GCC Countries
  • 11.2.2. Egypt
  • 11.2.3. South Africa
  • 11.2.4. Northern Africa
  • 11.2.5. Rest of Middle East & Africa
• 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Type, 2025-2032
  • 11.3.1. Lumbar Puncture
  • 11.3.2. Nerve Conduction
  • 11.3.3. Electromyography (EMG)
  • 11.3.4. Blood Test
  • 11.3.5. Other
• 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Syndrome Type, 2025-2032
  • 11.4.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 11.4.2. Miller Fisher Syndrome (MFS)
  • 11.4.3. Acute Motor Axonal Neuropathy (AMAN)
  • 11.4.4. Others
• 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By End-use, 2025-2032
  • 11.5.1. Hospitals and Clinics
  • 11.5.2. Diagnostic Laboratories
  • 11.5.3. Research & Academic Institutes
  • 11.5.4. Specialty Neurology Centers
• 11.6. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Cadwell Industries, Inc,
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Sources
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. Alpine Biomed
  • 12.3.3. Bionen Medical Devices
  • 12.3.4. Cardinal Health
  • 12.3.5. Clarity Medical
  • 12.3.6. Deymed Diagnostic
  • 12.3.7. EMS Biomedical
  • 12.3.8. Medtronic
  • 12.3.9. Natus Medical Incorporated
  • 12.3.10. Nihon Kohden
  • 12.3.11. Rochester Electro-Medical (LifeSync)
  • 12.3.12. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations